Xenogenic anticancer vaccine preclinical investigation in murine models.

A scientific R&D investigational project in oncology research. We have developed and patented unique anticancer vaccine based on xenogenic tumor associated antigens, able to stop tumor growth, progression and prolong animal life span in murine tumor models. Vaccine has now been tested in preclinical trial in murine tumor models. Non-rodent experimental work has left to be done to proceed to clinical trials in humans. This work is performed in partnership with National Cancer institute, Lithuania.

See the vaccine performance on animal models (PDF).